BioCryst Pharmaceuticals, Inc. (BCRX) — Stock Score Summary

BioCryst Pharmaceuticals, Inc. (BCRX) has a MoatMap StockRank of 93/100 based on Quality (60/100), Value (56/100), and Momentum (65/100) factor scores. The current signal is STRONG BUY. BioCryst is a commercial-stage biotech company with its primary asset, Orladeyo, for hereditary angioedema. While revenue is growing, the company has a history of share dilution and lacks the consistent profitability, high ROIC, and structural moat of a quality compounder.

BioCryst Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing oral, small-molecule medicines for patients with rare diseases. Its competitive moat is anchored by ORLADEYO, a proprietary oral drug offering a differentiated and convenient treatment for hereditary angioedema (HAE). BioCryst leverages its expertise in small-molecule drug development to address high unmet needs in niche patient populations.

Key Financial Metrics

Price$8.35
Market Cap$2.3B
P/E (Forward)12.46
Price/Book-3.89
Return on Invested Capital108.9%
Gross Margin76.6%
Operating Margin-2.5%
Revenue Growth7.5%
Free Cash Flow$264M

BioCryst Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is BioCryst Pharmaceuticals, Inc.’s (BCRX) StockRank?
MoatMap’s StockRank for BioCryst Pharmaceuticals, Inc. (BCRX) is 93/100, with a Strong Buy signal. It is a composite of Quality (60), Value (56), and Momentum (65) factor ranks across MoatMap’s 19,000+ stock universe.
Does BioCryst Pharmaceuticals, Inc. have an economic moat?
BioCryst Pharmaceuticals, Inc. (BCRX) has a Quality factor score of 60/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BioCryst Pharmaceuticals, Inc. a buy, hold, or sell?
MoatMap’s current signal for BioCryst Pharmaceuticals, Inc. (BCRX) is Strong Buy, based on a StockRank of 93/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BioCryst Pharmaceuticals, Inc. in?
BioCryst Pharmaceuticals, Inc. (BCRX) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (United States).
Browse all ranked stocksBCRX deep dive reportAI ChampionsHow we score stocksSense-check another stock